Skip to main content
    • Aa
    • Aa

Effectiveness of trivalent and monovalent influenza vaccines against laboratory-confirmed influenza infection in persons with medically attended influenza-like illness in Bavaria, Germany, 2010/2011 season

  • H. ENGLUND (a1) (a2), H. CAMPE (a1) and W. HAUTMANN (a1)

We estimated the vaccine effectiveness (VE) of trivalent and monovalent influenza vaccines, respectively, against laboratory-confirmed influenza infections in patients with influenza-like illness who visited physicians participating in the Bayern Influenza Sentinel in Bavaria, Germany during 2010/2011. Swab specimens were analysed for influenza A(H1N1)pdm09, A(H3) and B by PCR. VE was estimated using the test-negative case-control study design and logistic regression. In total, 1866 patients (790 cases, 1076 controls) were included. The VE of trivalent vaccines administered in season 2010/2011 against laboratory-confirmed infection with any influenza virus, adjusted for age group, sex, chronic illness and week of arrival of the specimen, was 67·8% [95% confidence interval (CI) 39·2–82·9)]. The adjusted VE of monovalent influenza vaccines administered in season 2009/2010 against laboratory-confirmed influenza A(H1N1)pdm09 infection in 2010/2011 was 38·6% (95% CI −70·0 to 77·8). This is the first VE study conducted in Bavaria. We concluded that the trivalent influenza vaccines were effective in our study population.

Corresponding author
*Author for correspondence: Ms H. Englund, Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Veterinärstraße 2, 85762 Oberschleißheim, Germany. (Email:
Hide All
1.Campe H, et al. Year-round influenza surveillance in Bavaria. Interim report of the Bayern Influenza Sentinel (BIS) season 2010/11 [in German]. Bayerisches Ärzteblatt 2011; 7: 424427.
2.Fachgebiet Impfpraevention (FG 33) der Abteilung Infektionsepidemiologie des Robert Koch-Instituts. Representative telephone survey concerning vaccinations against the pandemic influenza (H1N1) 2009. Results from interviews up to April 2010 [in German]. Epidemiologisches Bulletin 2010; 25. Robert Koch Institute, Berlin.
3.WHO. Recommended viruses for influenza vaccines for use in the 2010/2011 northern hemisphere influenza season. Revised 5 March 2010. ( Accessed 18 May 2011.
4.Anon. Recommendations from the German Standing Committee on Vaccination of the Robert Koch Institute. July 2009 [in German]. Epidemiologisches Bulletin 2009; 30. Robert Koch Institute, Berlin.
5.Anon. Recommendations from the German Standing Committee on Vaccination of the Robert Koch Institute. July 2010 [in German]. Epidemiologisches Bulletin 2010; 30. Robert Koch Institute, Berlin.
6.Buda S, et al. Report on the epidemiology of influenza in Germany season 2010/11 [in German]. Berlin, Germany: Robert Koch Institute, 2011.
7.Orenstein EW, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. International Journal of Epidemiology 2007; 36: 623631.
8.Valenciano M, et al. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States. Eurosurveillance 2008; 13(43): pii = 19015.
9.Kissling E, et al. ‘I-MOVE’ towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008–9. Eurosurveillance 2009; 14(44): pii = 19388.
10.Yin JK, et al. Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses. Vaccine 2012; 30: 32093222.
11.Huber I, et al. A multiplex one-step real-time RT-PCR assay for influenza surveillance. Eurosurveillance. 2011; 16(7): pii = 19798.
12.MWE Medical Wire. Σ-Transwab® and Σ-Virucult®, the new generation of preanalyticals ( Accessed 2 December 2011.
14.European Commission. European Commission Decision of 30 April 2009 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council, Luxembourg: Publications Office of the European Union, 1 May 2009. L110/58.
15.Valenciano M, et al. Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine 2010; 28: 73817388.
16.Jiménez-Jorge S, et al. Effectiveness of the 2010–11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine 2012; 30: 35953602.
17.Kissling E, et al. I-MOVE multi-centre case control study 2010–11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One. Published online: 15 November 2011. doi:10.1371/journal.pone.0027622.
18.Pebody RG, et al. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiology and Infection. Published online: 13 June 2012. doi:10.1017/S0950268812001148
19.Blank PR, et al. Trends in influenza vaccination coverage rates in Germany over six seasons from 2001/02 to 2006/07. Medizinische Klinik (Munich) 2008; 103: 761768.
20.Reuss AM, et al. Influenza vaccination coverage in the 2004/05, 2005/06, and 2006/07 seasons: a secondary data analysis based on billing data of the German Associations of Statutory Health Insurance Physicians. Deutsches Ärzteblatt International. 2010; 107: 845850.
21.Böhmer MM, et al. Seasonal influenza vaccine uptake in Germany 2007/2008 and 2008/2009: results from a national health update survey. Vaccine 2011; 29: 44924498.
22.Böhmer M, Walter D. Influenza virus vaccination in Germany – results of the German Health Update study (GEDA) 2009. GBE Kompakt 2. Robert Koch Institute, Berlin.
23.Langley JM, et al. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. Pediatric Infectious Disease Journal 2012; 31: 848858.
24.Nassim C, et al. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to <9 years of age. Pediatric Infectious Disease Journal 2012; 31: e59e65.
25.Saitoh A, et al. Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years. Human Vaccines & Immunotherapeutics 2012; 8: 749758.
26.Walker WT, et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clinical Infectious Diseases 2012; 54: 661669.
27.Ferguson M, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. Journal of Infectious Diseases 2012; 205: 733744.
28.Ikematsu H, et al. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Human Vaccines & Immunotherapeutics 2012; 8: 260266.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 1
Total number of PDF views: 21 *
Loading metrics...

Abstract views

Total abstract views: 99 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st October 2017. This data will be updated every 24 hours.